Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Respicardia's remedē Neurostimulator Improves Sleep Apnea Symptoms In Pivotal Trial

Executive Summary

The implantable neurostimulation system works automatically and continuously during every hour of sleep and does not depend on patient adherence, which has been a major limitation of continuous positive airway pressure therapy.

Advertisement

Related Content

DEVICE DEBUTS: Product And New Indication Launches From Medtronic, Strkyer, Siemens, And More
US Approvals Analysis: Original PMA Slowdown, De Novo Upswing Among Recent Trends
Starts & Stops: Respicardia Puts Sleep Apnea Device PAS On Snooze
Largest Sleep Apnea Trial Backs CPAP For Improving QoL, Not For Lowering Secondary Cardio Events
Sorin Gains Distribution Rights, Minority Stake In Respicardia’s remedē Sleep Apnea Device

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

MT103791

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel